For a research-based pharmaceutical company to be successful in the 1990s. it must have a strategic plan for the global development of new chemical entities. Global development can be defined as an attempt to reach all major markets as rapidly as possible and for many companies these will include the United States. Japan. Germany. France. Italy. UK and Canada. which together represent approximately 85% of the pharmaceutical market in the developed world. The mutual acceptance of foreign clinical data would reduce the time and resources required to develop a new medicine for the international market by eliminating the requirement for the routine repetition of clinical studies in local populations. In Japan this has been largely based on the belief that genetic differences in respon siveness may result in a different benefit/risk assessment for a new mediCine. while requests in Europe and the United States for local data relate mainly to methodological and cultural considerations. The importance of this issue has been recognised internationally as it was one of the topics discussed at the International Conference on Harmonisation in Orlando (October 1993) and it is currently on the programme for ICH3 which will be convened in Yokohama in Japan in November 1995.
There is currently limited acceptance of foreign clinical data by regulatory authorities, although the reasons for repeating studies are poorly defined. There are some proven genetic differences in drug metabolism and elimination which occur with varying frequencies in different populations. In addition, there are differences in culture, environment and medical practice which can impact on drug reponsiveness.
This book, a further edition in the CMR Workshop Series, reviews the proceedings of a workshop held in London in July 1993 to address these issues. The contributors review the current situation, address the scientific basis for repeating clinical trials in different ethnic groups, consider specific examples, and assess the relevance of interethnic and environmental differences in responsiveness for drug development.
"Sobre este título" puede pertenecer a otra edición de este libro.
Gastos de envío:
EUR 18,02
De Reino Unido a Estados Unidos de America
Gastos de envío:
GRATIS
A Estados Unidos de America
Librería: booksXpress, Bayonne, NJ, Estados Unidos de America
Soft Cover. Condición: new. Nº de ref. del artículo: 9789401046213
Cantidad disponible: 10 disponibles
Librería: Lucky's Textbooks, Dallas, TX, Estados Unidos de America
Condición: New. Nº de ref. del artículo: ABLIING23Apr0412070054739
Cantidad disponible: Más de 20 disponibles
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
Condición: New. Nº de ref. del artículo: 20348245-n
Cantidad disponible: 5 disponibles
Librería: Ria Christie Collections, Uxbridge, Reino Unido
Condición: NEW. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Nº de ref. del artículo: ria9789401046213_lsuk
Cantidad disponible: Más de 20 disponibles
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -For a research-based pharmaceutical company to be successful in the 1990s. it must have a strategic plan for the global development of new chemical entities. Global development can be defined as an attempt to reach all major markets as rapidly as possible and for many companies these will include the United States. Japan. Germany. France. Italy. UK and Canada. which together represent approximately 85% of the pharmaceutical market in the developed world. The mutual acceptance of foreign clinical data would reduce the time and resources required to develop a new medicine for the international market by eliminating the requirement for the routine repetition of clinical studies in local populations. In Japan this has been largely based on the belief that genetic differences in respon siveness may result in a different benefit/risk assessment for a new mediCine. while requests in Europe and the United States for local data relate mainly to methodological and cultural considerations. The importance of this issue has been recognised internationally as it was one of the topics discussed at the International Conference on Harmonisation in Orlando (October 1993) and it is currently on the programme for ICH3 which will be convened in Yokohama in Japan in November 1995. 284 pp. Englisch. Nº de ref. del artículo: 9789401046213
Cantidad disponible: 2 disponibles
Librería: GreatBookPricesUK, Castle Donington, DERBY, Reino Unido
Condición: New. Nº de ref. del artículo: 20348245-n
Cantidad disponible: 5 disponibles
Librería: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlanda
Condición: NEW. Editor(s): Walker, S.R.; Lumley, Cyndy E.; McAuslane, Neil. Series: Centre for Medicines Research Workshop. Num Pages: 262 pages, biography. BIC Classification: MBN; MMG. Category: (P) Professional & Vocational. Dimension: 240 x 160 x 15. Weight in Grams: 457. . 2012. Softcover reprint of the original 1st ed. 1994. Paperback. . . . . Nº de ref. del artículo: V9789401046213
Cantidad disponible: 15 disponibles
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - For a research-based pharmaceutical company to be successful in the 1990s. it must have a strategic plan for the global development of new chemical entities. Global development can be defined as an attempt to reach all major markets as rapidly as possible and for many companies these will include the United States. Japan. Germany. France. Italy. UK and Canada. which together represent approximately 85% of the pharmaceutical market in the developed world. The mutual acceptance of foreign clinical data would reduce the time and resources required to develop a new medicine for the international market by eliminating the requirement for the routine repetition of clinical studies in local populations. In Japan this has been largely based on the belief that genetic differences in respon siveness may result in a different benefit/risk assessment for a new mediCine. while requests in Europe and the United States for local data relate mainly to methodological and cultural considerations. The importance of this issue has been recognised internationally as it was one of the topics discussed at the International Conference on Harmonisation in Orlando (October 1993) and it is currently on the programme for ICH3 which will be convened in Yokohama in Japan in November 1995. Nº de ref. del artículo: 9789401046213
Cantidad disponible: 1 disponibles
Librería: moluna, Greven, Alemania
Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. For a research-based pharmaceutical company to be successful in the 1990s. it must have a strategic plan for the global development of new chemical entities. Global development can be defined as an attempt to reach all major markets as rapidly as possible a. Nº de ref. del artículo: 5831404
Cantidad disponible: Más de 20 disponibles
Librería: Kennys Bookstore, Olney, MD, Estados Unidos de America
Condición: NEW. Editor(s): Walker, S.R.; Lumley, Cyndy E.; McAuslane, Neil. Series: Centre for Medicines Research Workshop. Num Pages: 262 pages, biography. BIC Classification: MBN; MMG. Category: (P) Professional & Vocational. Dimension: 240 x 160 x 15. Weight in Grams: 457. . 2012. Softcover reprint of the original 1st ed. 1994. Paperback. . . . . Books ship from the US and Ireland. Nº de ref. del artículo: V9789401046213
Cantidad disponible: 15 disponibles